Sub-Q or IV treprostinil recommended by the American College of Chest Physicians (ACCP) as one of several options for treatment of PAH in patients with NYHA functional class II, III, or IV disease.12 13 25 Choice of PAH therapy should be individualized; consider factors such as disease severity, route of administration, potential adverse effects, and patient preference.12 13